

Highlights of This Issue 5341

5379


Molecular Pathways: Intercellular PTEN and the Potential of PTEN Restoration Therapy

Benjamin D. Hopkins and Ramon E. Parsons

SPECIAL FEATURES**CCR Translations**
5343 Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production

Karen E. Knudsen

See related article, p. 5547
5346 Matching Wits with Melanoma Brain Metastases: From Biology to Therapeutics

Hussein Tawbi

*See related article, p. 5537***CCR New Strategies**
5349 New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy

Krishnansu S. Tewari and Bradley J. Monk

CCR Perspectives in Drug Approval
5359 First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer

Laleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Amna Ibrahim, Robert Justice, Richard Pazdur, and Patricia Cortazar

CCR Drug Updates
5365 Ibrutinib for the Treatment of Mantle Cell Lymphoma

Alex F. Herrera and Eric D. Jacobsen

Molecular Pathways
5372 Molecular Pathways: Epigenetic Modulation of Wnt–Glycogen Synthase Kinase-3 Signaling to Target Human Cancer Stem Cells

Yannick D. Benoit, Borhane Guezguez, Allison L. Boyd, and Mickie Bhatia

Review

5384

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

Andreas R. de Biasi, Jonathan Villena-Vargas, and Prasad S. Adusumilli

CANCER THERAPY: CLINICAL

5392

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepora, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrupp, and Giuseppe Giaccone

PERSONALIZED MEDICINE AND IMAGING

5403

Qualification of a Noninvasive Magnetic Resonance Imaging Biomarker to Assess Tumor Oxygenation

Florence Colliez, Marie-Aline Neveu, Julie Magat, Thanh Trang Cao Pham, Bernard Gallez, and Bénédicte F. Jordan

CANCER THERAPY: PRECLINICAL

5412

mTOR Inhibitors Induce Cell-Cycle Arrest and Inhibit Tumor Growth in Epstein–Barr Virus–Associated T and Natural Killer Cell Lymphoma Cells

Jun-ichi Kawada, Yoshinori Ito, Seiko Iwata, Michio Suzuki, Yoshihiko Kawano, Tetsuhiro Kanazawa, Mohammed Nure Alam Siddiquey, and Hiroshi Kimura

Table of Contents

5423 Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non-Small Cell Lung Cancer Cells
Akriti Kharbanda, Hasan Rajabi, Caining Jin, Jeremy Tchaicha, Eiki Kikuchi, Kwok-Kin Wong, and Donald Kufe

5435 Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Martin Kerr, Helen E. Scott, Blaz Groselj, Michael R.L. Stratford, Katalin Karaszi, Naomi L. Sharma, and Anne E. Kiltie

5446 Inhibition of *NANOG/NANOGP8* Downregulates *MCL-1* in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
Abid R. Mattoo, Jingyu Zhang, Luis A. Espinoza, and J. Milburn Jessup

5456 Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8⁺ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFN γ
Ruey-Shyang Soong, Liwen Song, Janson Trieu, Jayne Knoff, Liangmei He, Ya-Chea Tsai, Warner Huh, Yung-Nien Chang, Wen-Fang Cheng, Richard B.S. Roden, T.-C. Wu, Cornelia L. Trimble, and Chien-Fu Hung

5468 The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness
Chellappagounder Thangavel, Ettickan Boopathi, Steve Ciment, Yi Liu, Raymond O' Neill, Ankur Sharma, Steve B. McMahon, Hestia Mellert, Sankar Addya, Adam Ertel, Ruth Birbe, Paolo Fortina, Adam P. Dicker, Karen E. Knudsen, and Robert B. Den

5483 Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
Ellen Weisberg, Atsushi Nonami, Zhao Chen, Erik Nelson, Yongfei Chen, Feiyang Liu, HaeYeon Cho, Jianming Zhang, Martin Sattler, Constantine Mitsiades, Kwok-Kin Wong, Qingsong Liu, Nathanael S. Gray, and James D. Griffin

5496 Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Naïke Casagrande, Marta Celegato, Cinzia Borghese, Maurizio Mongiat, Alfonso Colombatti, and Donatella Aldinucci

BIOLOGY OF HUMAN TUMORS

5507 Deficient Cutaneous Antibacterial Competence in Cutaneous T-Cell Lymphomas: Role of Th2-Mediated Biased Th17 Function
Kerstin Wolk, Hiroshi Mitsui, Katrin Witte, Sylke Gellrich, Nicholas Gulati, Daniel Humme, Ellen Witte, Melanie Gonsior, Marc Beyer, Marshall E. Kadin, Hans-Dieter Volk, James G. Krueger, Wolfram Sterry, and Robert Sabat

5517 Activating *FGFR2-RAS-BRAF* Mutations in Ameloblastoma
Noah A. Brown, Delphine Rolland, Jonathan B. McHugh, Helmut C. Weigel, Lili Zhao, Megan S. Lim, Kojo S.J. Elenitoba-Johnson, and Bryan L. Betz

5527 Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with *BRAF*^{V600} Mutations
Amanda D. Bucheit, Guo Chen, Alan Siroy, Michael Tetzlaff, Russell Broadbudd, Denai Milton, Patricia Fox, Roland Bassett, Patrick Hwu, Jeffrey E. Gershenwald, Alexander J. Lazar, and Michael A. Davies

5537 Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
Guo Chen, Nitin Chakravarti, Kimberly Aardalen, Alexander J. Lazar, Michael T. Tetzlaff, Bradley Wubbenhorst, Sang-Bae Kim, Scott Kopetz, Alicia A. Ledoux, Y.N. Vashisht Gopal, Cristiano Goncalves Pereira, Wanleng Deng, Ju-Seog Lee, Katherine L. Nathanson, Kenneth D. Aldape, Victor G. Prieto, Darrin Stuart, and Michael A. Davies
See related commentary, p. 5346



Table of Contents

5547 **Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer**



Matthew Fankhauser, Yuen Tan, Geoff Macintyre, Izhak Haviv, Matthew K.H. Hong, Anne Nguyen, John S. Pedersen, Anthony J. Costello, Christopher M. Hovens, and Niall M. Corcoran
See related commentary, p. 5343

5558 **Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response**

Peiwen Kuo, Scott V. Bratman, David B. Shultz, Rie von Eyben, Cato Chan, Ziwei Wang, Carmen Say, Aparna Gupta, Bill W. Loo Jr, Amato J. Giaccia, Albert C. Koong, Maximilian Diehn, and Quynh-Thu Le



AC icon indicates Author Choice



CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows immunohistochemical sections of xenografts derived from gemcitabine-sensitive CAL29 bladder cancer cells. Sections were stained for Dck, and nuclear positivity was quantified using Aperio scanscope software, using the Nuclear v9 algorithm. For details, see the article by Kerr and colleagues on page 5435 of this issue.



Clinical Cancer Research

20 (21)

Clin Cancer Res 2014;20:5341-5569.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/20/21>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/20/21>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.